Phase 2 Study Comparing Pembrolizumab With Intermittent/Short-term Dual MAPK Pathway Inhibition Plus Pembrolizumab in Patients Harboring the BRAFV600 Mutation
Phase of Trial: Phase II
Latest Information Update: 18 Sep 2017
At a glance
- Drugs Dabrafenib (Primary) ; Pembrolizumab (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Acronyms IMPemBra
- 14 Sep 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.
- 12 Sep 2017 Trial design of the study presented at the 42nd European Society for Medical Oncology Congress.
- 10 Jun 2017 Biomarkers information updated